Global Varicella Treatment Market – Industry Trends and Forecast to 2030

Global Varicella Treatment Market, By Treatment (Vaccines, Medication, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Varicella Treatment Market Analysis and Size

According to the Centers for Diseases Control and Prevention, in May 2021, Herpes zoster affected people aged 60 years and above at a rate of about 1 per 100 in the U.S. each year. Older people are more susceptible to herpes zoster because of weakened immune systems. The increasing demand for vaccination in many countries is expected to boost the demand for the varicella treatment market in the coming years.

Data Bridge Market Research analyses a growth rate in the varicella treatment market in the forecast period 2023-2030. The expected CAGR of the varicella treatment market tends to be around 4.50% in the mentioned forecast period. The market was valued at USD 1.6 billion in 2022, and it would grow to USD 2.28 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Varicella Treatment Market Scope and Segmentation

Market Definition

Varicella, also known as chickenpox, is an acute and highly contagious disease caused by the primary infection of varicella-zoster virus (VZV). It is highly transmissible through respiratory droplets or may infect another person through direct contact. The initial symptoms of clinical varicella generally appear after a 10-21-day incubation period, including fever, malaise, and the characteristic itchy rash.  

Global Varicella Treatment Market Dynamics

Drivers

• Growing Awareness About Vaccines

Varicella vaccines are primarily used for measles, chickenpox, herpes zoster and mumps, rubella, and varicella immunization. Chickenpox can be serious, particularly in babies, adults, pregnant women, adolescents, and people with low immunity systems. Thus immunization in newborns is recommended by the WHO. Growing awareness associated with the use of varicella vaccines, growing immunization programs, and the rise in adoption of varicella vaccination worldwide also boost the growth of the varicella treatment market.

• Immunization Towards Chickenpox

Varicella vaccines are more efficient in building immunity against the varicella-zoster virus as the infection can cause severe diseases such as chickenpox and herpes zoster. Immunization against these diseases is essential as chickenpox can lead to severe complications such as bacterial infections of the skin and soft tissues in children and is also seen in adults in tropical countries like India. Growing demand for vaccination in many countries is anticipated to boost the demand for the varicella market in the upcoming years.

Opportunities

• Rising Rate of Campaigns and Initiatives

There are numerous campaigns that are being conducted in the U.S. to immunize people against the varicella vaccine to prevent diseases. For Instance, in October 2021, Measles, mumps, rubella (MMR), and varicella (chickenpox) vaccinations for Afghan evacuate who are temporarily staying at eight military installations in the U.S. were administered nationwide as part of Operation Allies Welcome (OAW). This effort led to the vaccination of more than 49,000 Afghan refugees nationwide. Furthermore, vaccinations are being given to evacuates at staging locations in Europe and the Middle East.

• Increasing Demand for Retail Pharmacies

The rise in the number of varicella therapeutics delivered through retail pharmacies and more retail pharmacies in highly developed countries creates opportunities for market expansion. Additionally, patients choose retail pharmacies over other types for purchasing drugs, as these are easily available.

 Restraints/Challenges

• Lack of skilled professionals

The lack of appropriate healthcare professionals who are unable to treat the patients with suitable treatments could limit the growth of the global varicella treatment market over a forecast period.

• Unavailability of Vaccinations

There is wide unavailability of vaccines that is hampering the market growth. Vaccination for varicella is not available in these regions. It was recorded that Thailand, Timor Lester, Macedonia, Tajikistan, and Syria accounted for the biggest number of varicella infection cases as of 2013, but there was a lack of vaccines and medicines that hampered the market growth.

This global varicella treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global varicella treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Varicella Treatment Market

The SARS-CoV-2 that causes coronavirus disease has been associated with T-cell immunological dysfunction. Patients suffering from COVID-19 are more likely to experience reactivation of herpes zoster due to the functional impairment and decline in T lymphocytes, predominantly CD4+ T cells, CD8+ T cells, and natural killer cells. Furthermore, the study titled "Herpes zoster in the era of COVID-19: A prospective observational study to probe the association of herpes zoster with COVID 19 infection and vaccination" published in the National Library of Medicine in June 2022, it has been reported that during post-marketing surveillance, reactivation of the varicella-zoster virus has occasionally been reported post vaccination for SARS-CoV-2. Thus, during the ongoing COVID-19 outbreak, managing varicella infection has become more critical.

Recent Developments:

• In January 2022, Pfizer Inc. collaborated with BioNTech S.E. to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring, and painful disease which impacts about one in three people in the U.S. during their lifetime.
• In July 2021, GlaxoSmithKline plc reported that the U.S. FDA had approved Shingrix to prevent herpes zoster in adults aged 18 years and above who are at higher risk of developing the disorder because of immunodeficiency

Global Varicella Treatment Market Scope

The global varicella treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Vaccines
• Medication
• Others

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Varicella Treatment Market Regional Analysis/Insights

The global varicella treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global varicella treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has witnessed positive global varicella treatment market growth throughout the forecasted period due to major key players and increased healthcare expenditure.

Asia-Pacific dominates the market due to the increased prevalence of varicella infection and easily availability of drugs in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Varicella Treatment Market Share Analysis

The global varicella treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global varicella treatment market

Key players operating in the global varicella treatment market include:

• Mylan N.V. (U.S.)

• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• BIO-MED (India)
• Intercept Pharmaceuticals, Inc (U.K.)
• Emcure Pharmaceuticals Limited(India)
• Changchun BCHT Biotechnology Co. (China)
• Novo Medi Sciences (India)

Research Methodology: Global Varicella Treatment Market  

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-55676